<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592643</url>
  </required_header>
  <id_info>
    <org_study_id>22760</org_study_id>
    <nct_id>NCT01592643</nct_id>
  </id_info>
  <brief_title>Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain</brief_title>
  <acronym>Nexis-CS0032</acronym>
  <official_title>Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if an investigational thin shield over the&#xD;
      cornea can safely and effectively reduce or eliminate pain following Post Photorefractive&#xD;
      Keratectomy (PRK).&#xD;
&#xD;
      The thin shield is made of silicone. The materials used to make the corneal shield all have a&#xD;
      history of use in medical devices, contact lenses, and/or corneal shields and have been used&#xD;
      safely in the eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2012</start_date>
  <completion_date type="Actual">October 31, 2013</completion_date>
  <primary_completion_date type="Actual">October 31, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pain Score of Four or Greater. Score Range: 0-10, Higher Score Corresponds to More Pain.</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Uncorrected Visual Acuity</measure>
    <time_frame>Six months</time_frame>
    <description>LogMAR uncorrected visual acuity. Values closer to zero indicate improved vision</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pain</condition>
  <condition>Vision Nearsighted</condition>
  <arm_group>
    <arm_group_label>Eye shield</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive eye shield during PRK surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eye Shield</intervention_name>
    <description>The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.</description>
    <arm_group_label>Eye shield</arm_group_label>
    <other_name>Nexis Vision corneal shield</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria.&#xD;
&#xD;
          -  Subjects age 18 and older with healthy eyes.&#xD;
&#xD;
          -  Nearsightedness between -0.50 diopters and -11.00 diopters with or without astigmatism&#xD;
             of up to 3.50 diopters.&#xD;
&#xD;
        Exclusion criteria.&#xD;
&#xD;
          -  Subjects under the age of 18.&#xD;
&#xD;
          -  Patients with excessively thin corneas.&#xD;
&#xD;
          -  Patients with topographic evidence of keratoconus.&#xD;
&#xD;
          -  Patients with ectactic eye disorders.&#xD;
&#xD;
          -  Patients with autoimmune diseases.&#xD;
&#xD;
          -  Patients who are pregnant or nursing.&#xD;
&#xD;
          -  Any other anterior segment abnormality other than that associated with PRK&#xD;
&#xD;
          -  Any abnormalities associated with the eye lids&#xD;
&#xD;
          -  Uncontrolled blepharitis or dry eye&#xD;
&#xD;
          -  Prior laser treatment of the retina&#xD;
&#xD;
          -  Any ophthalmic surgery performed within three (3) months prior to study excluding PRK&#xD;
             or LASIK&#xD;
&#xD;
          -  Diagnosis of glaucoma&#xD;
&#xD;
          -  Active diabetic retinopathy&#xD;
&#xD;
          -  Clinically significant inflammation or infection within six (6) months prior to study&#xD;
&#xD;
          -  Uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of&#xD;
             the Investigator&#xD;
&#xD;
          -  Participation in any study involving an investigational drug within the past 30&#xD;
             calendar days, or ongoing participation in a study with an investigational material&#xD;
&#xD;
          -  Intolerance or hypersensitivity to topical anesthetics, antibiotics, steroids or any&#xD;
             other pharmaceuticals that may be used pre and post surgically Specifically known&#xD;
             intolerance or hypersensitivity to contact lenses or any component of the&#xD;
             investigative material&#xD;
&#xD;
          -  A medical condition, serious concurrent illness, or extenuating circumstance that&#xD;
             would significantly decrease study compliance, including all prescribed follow-up&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would jeopardize the safety of&#xD;
             the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>SÃ¡les CS, Manche EE. Prospective evaluation of a novel silicone corneal shield after PRK: 6-month efficacy, safety, and predictability outcomes. Clin Ophthalmol. 2019 Jan 7;13:115-121. doi: 10.2147/OPTH.S183120. eCollection 2019.</citation>
    <PMID>30662255</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>November 24, 2021</results_first_submitted>
  <results_first_submitted_qc>November 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2021</results_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Corneal shield</keyword>
  <keyword>PRK</keyword>
  <keyword>Myopia</keyword>
  <keyword>Pain</keyword>
  <keyword>Vision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 19, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01592643/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eye Shield</title>
          <description>Participants receive eye shield during PRK surgery&#xD;
Eye Shield: The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eye Shield</title>
          <description>Participants receive eye shield during PRK surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Score of Four or Greater. Score Range: 0-10, Higher Score Corresponds to More Pain.</title>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eye Shield</title>
            <description>Participants receive eye shield during PRK surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Score of Four or Greater. Score Range: 0-10, Higher Score Corresponds to More Pain.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Uncorrected Visual Acuity</title>
        <description>LogMAR uncorrected visual acuity. Values closer to zero indicate improved vision</description>
        <time_frame>Six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eye Shield</title>
            <description>Participants receive eye shield during PRK surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Uncorrected Visual Acuity</title>
          <description>LogMAR uncorrected visual acuity. Values closer to zero indicate improved vision</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month six</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eye Shield</title>
          <description>Participants receive eye shield during PRK surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward E. Manche</name_or_title>
      <organization>Stanford University School of Medcine</organization>
      <phone>6507255765</phone>
      <email>edward.manche@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

